Next Article in Journal
Blood Pressure-Lowering Aspects of Lipid-Lowering and Anti-Diabetic Drugs
Previous Article in Journal
Pharmacogenetics of SSRIs and Sexual Dysfunction
Previous Article in Special Issue
The Art of Managing Conversions between Antiepileptic Drugs: Maximizing Patient Tolerability and Quality of Life
Article Menu

Export Article

Commentary of Pharmaceuticals 2010, 3(6), 1909-1935.

Open AccessCommentary
Pharmaceuticals 2010, 3(12), 3629-3632; doi:10.3390/ph3123629

Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’

BIAL - Portela & Ca, S.A., S. Mamede do Coronado, Portugal
*
Author to whom correspondence should be addressed.
Received: 9 November 2010 / Accepted: 16 December 2010 / Published: 17 December 2010
(This article belongs to the Special Issue Antiepileptic Drugs)
View Full-Text   |   Download PDF [49 KB, 20 December 2010; original version 17 December 2010]   |  

Abstract

The recent review of Matthew D. Krasowski on ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’ is a useful foundation of comparative interpretations on our current knowledge about therapeutic drug monitoring. Within the review, the statement that therapeutic drug monitoring has a minimal role in the therapeutic use of eslicarbazepine acetate due to its relatively predictable pharmacokinetics reflects the existing body of evidence although some information such as eslicarbazepine acetate’s chemical structure, proportions of its metabolites, their pharmacokinetics and chiral method of plasma level measurement need to be revised. These critical characteristics differentiate the novel compound from former dibenzazepines such as carbamazepine and oxcarbazepine in its clinical effects and needs for therapeutic drug monitoring.
Keywords: anticonvulsants; anti-epileptic drugs; drug monitoring; drug toxicity; epilepsy; seizures; carbamazepine; oxcarbazepine; eslicarbazepine acetate anticonvulsants; anti-epileptic drugs; drug monitoring; drug toxicity; epilepsy; seizures; carbamazepine; oxcarbazepine; eslicarbazepine acetate
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Öztiryaki, A.H.; Soares-da-Silva, P. Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’. Pharmaceuticals 2010, 3, 3629-3632.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top